Advertisements

Dequadin Lozenges

Quick links to important sections

Dequadin Lozenges

Advertisements
Advertisements

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Dequadin Lozenges

Quick Facts

Property Description
Active ingredient Dequalinium chloride
Form Lozenges (Solid oral mucosal delivery)
Pharmacological class Antiseptic (Local Anti-infective)
Common use Microbial control in the mouth and throat
Origin Synthetic compound

Dequadin Lozenges is a synthetic pharmaceutical preparation defined by its single active ingredient, Dequalinium chloride. It is classified pharmacologically as a local anti-infective and is primarily utilized for its potent antiseptic properties in the oropharyngeal cavity. This product functions as a monotherapy agent, focusing its entire therapeutic function on the chemical action of Dequalinium against microorganisms.

What Type of Medicine is Dequadin Lozenges?

Dequadin Lozenges is a topical antiseptic agent, distinct from systemic antibiotics, with action confined to the application site in the mouth and throat. The Dequalinium molecule is chemically categorized as a quaternary ammonium compound class. This classification identifies it as a surface-active agent, enabling it to physically disrupt the structure of microbial cells directly. The substance possesses recognized activity against pathogens frequently involved in oral infections, and the preparation is utilized for its ability to neutralize microbial threats in the oral cavity.

Composition and Dosage Form: The Dequalinium Lozenge

The preparation consists of the active substance, Dequalinium chloride, formulated within a solid matrix known as a lozenge. This pharmaceutical preparation is designed as an oral mucosal delivery system, facilitating the controlled and gradual release of the compound over time. This targeted delivery method represents a key differentiation point from liquid antiseptic solutions, as the lozenge format ensures extended local exposure of the active agent to the oral and pharyngeal membranes. The preparation is suited for bactericidal and fungicidal action, highlighting its ability to kill both bacteria and fungi contributing to local issues.

General Purpose in Oropharyngeal Hygiene

The central purpose of the Dequadin Lozenges preparation is to achieve localized control over the microbial population contributing to common oropharyngeal infections. The Dequalinium compound exhibits robust bactericidal and fungicidal activity, targeting pathogens through direct cell membrane disruption. By reducing the concentration of these microorganisms, the product’s function is to assist in maintaining local oral hygiene and addressing the underlying microbial factor associated with irritation in the mouth and throat.

Advertisements

What side effects are possible with Dequadin Lozenges?

Possible Side Effects and Safety Information

This section describes the adverse reactions and safety characteristics of Dequalinium chloride lozenges as classified and documented in official government regulatory information.


Documented Adverse Reactions

The official safety profile primarily lists effects related to the application site and the immune system, consistent with a topical medication.

Classification Group Examples of Adverse Reactions
Immune System Disorders Local hypersensitivity reactions, which can involve manifestations like rash.
General & Administration Site Conditions Local irritation, a burning sensation, or soreness of the tongue.

In many regulatory documents, the frequency of these adverse reactions is classified as not known because the incidence rate cannot be reliably estimated from available data. The System-Organ Classes involved are generally Immune system disorders, Skin and subcutaneous tissue disorders, and General disorders and administration site conditions.


Safety Constraints and Considerations

The most critical safety constraint documented is the potential for allergic reactions, which, if severe, are considered a serious outcome of hypersensitivity that necessitates immediate cessation of use. Excessive or high-dose use may also lead to gastrointestinal discomfort.

Contraindication: The medicine is strictly contraindicated in individuals who have a known hypersensitivity to Dequalinium chloride or any of the lozenge's excipients.

Special Populations: The official label for Dequalinium chloride specifies that no dosage adjustment is required for older adults. However, the safety of the medicine during pregnancy and lactation has not been formally established.

Discontinuation Note: Use of the lozenge must be discontinued if symptoms persist or worsen during the course of treatment, or if signs of an allergic reaction appear.

Advertisements

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — official regulatory information for Dequadin Lozenges

The following information is derived strictly from the content of official government regulatory documents, such as the Summary of Product Characteristics (SmPC) for Dequalinium chloride lozenges.

Feature Regulatory Statement (Official Labeling)
Documented overdose presentations Gastrointestinal discomfort is the specific adverse effect listed as the anticipated manifestation of overdosage.
Physiological systems affected (as stated in label) The primary system affected by overdosage, as documented, is the gastrointestinal tract.
Emergency-response statements (as written in official documents) Treatment should be symptomatic.
When immediate medical help is required (label-derived phrasing only) Urgent medical help is required if symptoms are severe or persistent, necessitating professional supportive care.

Overdose classifications (high-level)

Classification Aspect Regulatory Statement (Official Labeling)
Severity classification (as defined in official documents) Overdosage is officially documented as not expected to present a problem other than the documented gastrointestinal discomfort.
Regulatory basis (EMA / FDA / etc.) Based on the official Summary of Product Characteristics (SmPC) provided by national medicines authorities.

Resulting overdose structure

Official overdose statements:

  • Overdosage is not expected to present a problem other than the manifestation of gastrointestinal discomfort.
  • No specific antidote is mentioned in the official regulatory documentation.
  • The management of overdosage is officially mandated as symptomatic treatment.

Connection to the overall overdose profile (2–4 sentences): Official regulatory documents define the overdose profile for Dequadin Lozenges by stating that overconsumption should not result in severe systemic complications beyond gastrointestinal discomfort. This limited severity classification dictates the mandated emergency action, which is focused exclusively on providing symptomatic treatment. The guidance for seeking help is thus tied to managing and resolving the documented, non-life-threatening manifestation.

Advertisements

Therapeutic Uses of Dequadin Lozenges

The therapeutic scope of Dequadin Lozenges is applied across domains where additional symptomatic support is needed for infections affecting the mouth and throat. This medication is relevant in contexts marked by increased discomfort or tension.


The lozenges are commonly used to ease symptoms associated with sore throat (pharyngitis and tonsillitis). They are also considered relevant for conditions characterized by periods of heightened symptoms, including oral thrush (candidiasis), stomatitis, and gingivitis. The medication is utilized in clinical settings that involve acute or disruptive symptom patterns, and plays a role in managing symptoms that create noticeable physiological strain.

“The medication is relevant when symptoms cluster into patterns requiring short-term symptomatic assistance.”

This short-term symptomatic assistance helps address symptom clusters that may become intense or disruptive, such as the discomfort of tender aphthous ulcers (canker sores) or acute localized inflammation that interferes with daily functioning. It contributes to improved comfort during symptomatic periods and may assist with maintaining functional stability.


Quick Fact: Relief for Localized Discomfort Dequadin Lozenges are primarily used for managing symptoms related to localized discomfort, pain, and irritation associated with symptoms related to inflammatory or irritative states in the mouth and throat. It is applied when short-term symptomatic assistance is needed.

Regulatory References

  1. Nigerian NAFDAC Product Information
Advertisements

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Regulatory agencies define the eligibility for Dequadin Lozenges based on hypersensitivity, age, and physiological state.

Classification Status Rationale (Official Labeling)
Contraindicated Must Not Use Hypersensitivity (allergy) to dequalinium chloride or any of the product's excipients.
Established Use Generally Allowed Adults, and children over the minimum age specified (commonly 6 or 10 years, depending on the region).
Restricted Use Not Recommended Pregnancy and Lactation (breastfeeding), as the safety of the product has not been established in these populations.

No specific dose adjustment is documented as necessary for older adults. Eligibility for children younger than the specified age limit is not established. The primary factor precluding use is a documented allergy to the active ingredient or other components.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Dequadin Lozenges (Dequalinium chloride monotherapy) is primarily defined by the authoritative regulatory finding that no clinically significant drug interactions are known. This high-level statement, established in government prescribing information, dictates the absence of specific warnings across various interaction classifications.


Official Interaction Status

Classification Official Regulatory Finding
Contraindicated Combinations None formally documented. The official label does not prohibit co-administration with any specific medicinal products based on an interaction risk.
Pharmacokinetic or Pharmacodynamic Interactions None officially documented. The regulatory profile does not list any specific interactions involving CYP enzyme metabolism, drug transporters, or additive pharmacodynamic effects.
Food, Alcohol, or Substance Interactions None officially documented. The regulatory prescribing information does not specify any formal interactions with food, alcohol, herbal products, or supplements.
Timing-Based Rules None officially documented. No mandatory requirements for separating the administration time of Dequadin Lozenges from other medicines are contained in the official labeling.

Connection to the Overall Interaction Profile

The structure of the official regulatory information confirms that the product's use is not constrained by formally documented interaction warnings. There are no known interactions that necessitate specific limitations on co-administration, timing separation, or warnings regarding exposure modification based on the government documents.

Advertisements

Mechanism of Action

Dequadin Lozenges contain Dequalinium Chloride, a quaternary ammonium compound that exhibits antimicrobial activity against susceptible bacteria, fungi, and yeast. The mechanism of action is localized and involves two major domains of cellular disruption.

Microbial Cell Membrane Disruption

This domain involves the physical-chemical interaction of the drug with the microbial cell envelope. Dequalinium Chloride is a cationic surfactant that integrates into the negatively charged cell membranes of the target microorganisms. This integration compromises the membrane's structural integrity, increasing its permeability and facilitating the loss of essential intracellular components. This cascade results in the irreversible cessation of microbial cell function.

Internal Macromolecule Interference

Following the membrane breach, the drug penetrates the microbial cell interior, where it further interferes with vital processes. It causes the precipitation of essential intracellular proteins and nucleic acids (DNA/RNA), effectively denaturing these macromolecules. This internal damage halts the microbe's metabolism, energy production, and reproductive (proliferation) capability, which consequently halts microbial proliferation.

Advertisements

Dosage and Administration Information

The administration of Dequadin Lozenges is defined by specific usage guidelines, focusing exclusively on the correct application of the 0.25 mg Dequalinium chloride unit. The established route of administration is oral, designed for local mucosal delivery within the oropharyngeal cavity.

Standard Dosing Regimen and Frequency

The prescribed single dose is one lozenge per administration. The dosing schedule dictates that this may be repeated every 2 to 3 hours, strictly as required for intermittent use. A firm limit is placed on consumption: administration must not exceed a maximum of 8 lozenges within a 24-hour period. This maximum establishes the high-level boundary for consumption.

Administration Method and Population Rules

The specific method of use is crucial for this product's targeted action. The lozenge must be sucked slowly until fully dissolved; it is not intended to be chewed, crushed, or swallowed whole. This procedural requirement ensures the controlled and gradual release of the active ingredient directly onto the target mucosal surface.

The standardized regimen is intended for adults and children over 10 years of age. Older adults do not require a reduction or adjustment to the standard dose. Consistent with the intended short-term symptomatic use, if the condition or symptoms persist, consultation with a physician is the recommended procedural step.

Advertisements

Recent Clinical Evidence

Dequadin Lozenges: Recent Clinical Evidence

The active ingredient in Dequadin Lozenges is dequalinium chloride, a quaternary ammonium antiseptic. The lozenges are intended for local therapy to help relieve symptoms of mild infections of the mouth and throat, such as sore throat, pharyngitis, and minor oral ulcers.


Research on Efficacy

Clinical studies have explored the effect of dequalinium chloride on symptoms associated with acute pharyngitis (sore throat).

  • Symptom Relief: In randomized, placebo-controlled trials, lozenges containing dequalinium were evaluated for their impact on symptoms like throat pain and difficulty swallowing. The analysis indicated a difference in the percentage of adult participants achieving complete resolution of these symptoms, favoring the lozenge group over placebo at the 72-hour mark.
  • Targeted Action: Dequalinium chloride has shown activity against a range of gram-positive and gram-negative bacteria, as well as yeasts and fungi, which are often associated with mouth and throat infections. The lozenge formulation provides direct application of the agent to the mucosal surfaces of the mouth and throat.

Special Considerations

The evidence suggests that while dequalinium chloride may assist with local symptoms in the majority of acute non-streptococcal infections, it does not typically influence systemic symptoms, such as fever or widespread infection markers. For conditions caused by specific pathogens like hemolytic streptococci, primary treatment with systemic antibiotics is usually required.

Long-term effects and the full safety profile of dequalinium chloride, particularly when used repeatedly over extended periods, continue to be monitored.

Key Studies & References

  1. National Institute for Health and Care Excellence (NICE) Guideline NG134: Sore throat (acute): antimicrobial prescribing
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Dequadin Lozenges (FAQ)


Q: How long does the effect of one Dequadin lozenge typically last?

The medicine is designed for intermittent use to help relieve symptoms. According to the official dosing schedule, the lozenge may be repeated every 2 to 3 hours, strictly as needed. This interval is the established period during which re-administration may be considered, according to regulatory guidelines.


Q: Is it common to feel a slight numbing sensation after taking a lozenge?

Regulatory safety profiles for Dequadin Lozenges do not typically list a numbing sensation as one of the known or reported effects of the active ingredient, dequalinium chloride. The active ingredient functions primarily as a local antiseptic, not a local anesthetic.


Q: What if I accidentally swallow the lozenge whole?

The lozenge is intended to be slowly dissolved in the mouth to ensure the active ingredient is released locally. Official safety data indicates that consuming a higher-than-recommended amount may potentially lead to transient gastrointestinal discomfort. The safety profile does not indicate serious consequences from a single ingestion, focusing instead on potential discomfort.


Q: Are Dequadin Lozenges safe for people with diabetes?

The standard formulation of the lozenge lists both icing sugar and liquid glucose among its excipients (inactive ingredients). Individuals managing blood sugar levels are informed of the presence of these excipients. Some regulatory databases may list an alternative sugar-free formulation of dequalinium chloride lozenges.


Q: What are the less common side effects reported with Dequadin?

Officially documented undesirable effects are primarily limited to local hypersensitivity reactions, such as a rash, and soreness or irritation of the tongue. The frequency of most other potential effects is classified in official documents as not known because the incidence rate cannot be reliably estimated from available data.


Q: Is there a maximum number of days Dequadin is generally recommended for use?

The product is authorized for short-term symptomatic use. Official guidance advises consulting with a physician if the condition persists or worsens during the course of treatment, as this may indicate a need for further evaluation.


Q: Does Dequadin have any known effects on teeth or oral health?

Official safety documents list local adverse reactions such as soreness of the tongue. However, there are no known long-term or structural effects on the teeth listed in the regulatory safety profiles for this product.


Q: Are there specific storage instructions for Dequadin Lozenges?

Official documents require the lozenges to be stored in their original packaging and kept out of the sight and reach of children. They must also be kept in a cool, dry place and maintained at a temperature that does not exceed 25 C.


Q: Does prolonged use of Dequadin Lozenge cause any oral side effects?

The product information advises against use beyond the recommended duration. Official safety documents state that prolonged use may be associated with effects such as irritation or soreness of the mouth or tongue.


Q: Can Dequadin be used for mouth ulcers?

Official regulatory information lists aphthous ulcers as one of the conditions for which the lozenges are indicated for local therapy in the mouth and throat.


Q: Does Dequadin contain sugar or is it sugar-free?

The standard formulation of the lozenge lists icing sugar and liquid glucose as excipients (non-active ingredients). Some regulatory databases, however, may list specific sugar-free formulations of dequalinium chloride lozenges.


Q: Can Dequadin Lozenges cause stomach upset?

While not listed as a common adverse reaction at recommended doses, official information indicates that gastrointestinal discomfort may be a consequence if the medicine is consumed in amounts higher than the maximum daily limit.


Q: Do Dequadin Lozenges expire, and does the effectiveness change after the expiration date?

Like all medicines, Dequadin Lozenges have a defined shelf life which is stated in the regulatory product information. The product information states the product is not intended for use past the printed expiration date.


Q: Does Dequadin affect the ability to drive or operate machinery?

Official regulatory documentation states that no adverse effects on the ability to drive or use machinery are known or documented for this medicine.


Q: Is it normal to have a slight change in taste while using Dequadin?

Alteration in taste is a reported effect associated with Dequalinium chloride lozenges, and it is documented within the safety profile of the medicine.


Q: Are there different strengths of Dequadin Lozenges available?

Official regulatory information specifies the strength of the active ingredient as 0.25 mg of dequalinium chloride per lozenge. This is the standardized strength for this preparation.


Q: Do Dequadin Lozenges contain any ingredients derived from animals?

The list of excipients (non-active ingredients) in the lozenge formulation includes gelatin. Individuals with specific dietary or religious restrictions may wish to consult the full excipient list.


Q: Has there been research on Dequadin use in older adults?

Official regulatory guidance confirms that older adults do not require a reduction or adjustment to the standard dose. This means the use of the product in this population was considered during the assessment process.


Q: What should I do if I think I've taken too many lozenges?

The maximum daily limit should not be exceeded. Official regulatory information advises that overdosage should not present a problem beyond possible gastrointestinal discomfort. Official guidance includes seeking medical advice for situations involving potential overdosage.


Q: Can people with lactose intolerance use Dequadin?

The official excipient lists for this lozenge formulation generally do not include lactose. Individuals with specific intolerance concerns may wish to verify the ingredients on the product labeling.


Q: Is Dequadin available over-the-counter or does it require a prescription?

In many regions where it is available, the product is classified for use as an Over-The-Counter (OTC) medicine, meaning it can be purchased without a doctor's prescription.

Advertisements

How should Dequadin Lozenges be stored and disposed of?

Storage and Disposal of Dequadin Lozenges

Official regulatory labeling dictates specific conditions for storing Dequadin Lozenges to ensure product stability. The lozenges must be stored at a controlled temperature, not exceeding 25°C (or 30^circC in certain regions), and kept in a cool, dry place. The product should remain in its original container (blister strips and carton).

To meet safety requirements, the medicine must be kept out of the sight and reach of children at all times.

Regarding disposal, official documentation states that there are no special requirements for discarding the unused medicinal product. Expired or unused lozenges should be disposed of according to local requirements and must not be flushed down the toilet or placed in wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Dequadin Lozenges found in:

A-Z Index: